Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical
Executive Summary
With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations